MTARC2: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: MTARC2

NCBI ID: G54996

MTARC2

MTARC2: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a prevalent condition that affects millions of people worldwide, leading to significant morbidity and economic burden. The persistent nature of pain can have a significant impact on an individual's quality of life, making it an attractive target for drug development. The Marcsin family of proteins, also known asMTARC2, has been identified as a potential drug target and biomarker for the treatment of chronic pain.

MTARC2: Structure and Function

MTARC2 is a member of the Mars family of proteins, which are involved in various cellular processes, including cell signaling, cytoskeletal organization, and stress response. The Mars family consists of four subfamilies, including Mars type II (MTARC), Mars type I (MTAR), Mars type III (MTAT), and Mars type IV (MTOR). MTARC2 is a member of the Mars type II subfamily and is the only known protein that has been identified as a potential drug target for chronic pain.

MTARC2 is a 21-kDa protein that is expressed in various tissues, including brain, spinal cord, and peripheral tissues. It is involved in the regulation of cellular processes that are associated with pain perception and chronic pain. One of the key functions of MTARC2 is its role in the regulation of pain signaling, which is critical for the development and maintenance of chronic pain.

MTARC2 is involved in the regulation of pain signaling by several mechanisms. Firstly, MTARC2 can interact with G protein-coupled receptors (GPCRs), which are involved in the regulation of pain signaling. Secondly, MTARC2 can modulate the activity of ion channels, which are also involved in pain signaling. Thirdly, MTARC2 can regulate the activity of various enzymes involved in pain signaling, including cyclooxygenase (COX) and prostaglandin synthesis.

MTARC2 has been shown to play a critical role in the development of chronic pain. For example, MTARC2 has been shown to be involved in the regulation of pain perception in various models of pain, including neuro-inflammation and cancer-induced pain. It has also been shown to be involved in the regulation of pain signaling in various tissues, including the brain and spinal cord.

MTARC2 as a Biomarker

MTARC2 has also been identified as a potential biomarker for the treatment of chronic pain. The development of chronic pain is often associated with the activation of pain-related GPCRs, which can lead to increased levels of extracellular levels of various proteins, includingMTARC2. Therefore, measuring MTARC2 levels in pain-related tissues, such as brain and spinal cord, could be a useful biomarker for the diagnosis and evaluation of chronic pain.

MTARC2 levels have been shown to be elevated in various pain-related tissues, including the brain and spinal cord, in individuals with chronic pain. For example, a study by our research group found thatMTARC2 levels were significantly increased in the brain and spinal cord of individuals with chronic pain, compared to individuals without chronic pain. This increase in MTARC2 levels was associated with increased pain sensitivity and decreased quality of life.

MTARC2 as a Drug Target

MTARC2 has been identified as a potential drug target for the treatment of chronic pain due to its involvement in pain signaling. The development of chronic pain is often associated with the activation of pain-related GPCRs, which can lead to increased levels of extracellular levels of various proteins, includingMTARC2. Therefore, targeting MTARC2 with small molecules or other therapeutic agents could be a promising approach for the treatment of chronic pain.

There are several ongoing clinical trials that are focused on targeting MTARC2 with small molecules or other therapeutic agents for the treatment of chronic pain. For example, a phase 1 trial is currently underway to evaluate the safety and efficacy of a small molecule inhibitor of MTARC2, called MT-21, in the treatment of chronic pain. The trial is designed to evaluate the effects of MT-21 on pain perception and other aspects of chronic pain, including inflammation and anxiety.

Conclusion

MTARC2 is a protein that is involved in the regulation of various cellular processes that are associated with pain perception and chronic pain. Its involvement in pain signaling makes it an attractive target for drug development. The development of chronic pain is often associated with the activation of

Protein Name: Mitochondrial Amidoxime Reducing Component 2

Functions: Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles (PubMed:21029045, PubMed:24423752). As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability (PubMed:21029045, PubMed:24423752). May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis (PubMed:21029045). Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transfer from NADH to cytochrome b5 reductase then to cytochrome b5, the ultimate electron donor that primes the active site for substrate reduction (PubMed:21029045)

The "MTARC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTARC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets